What Kalbe International does

Kalbe International is the international marketing and export subsidiary of PT Kalbe Farma Tbk, the largest publicly-listed pharmaceutical company in Southeast Asia. Headquartered in Jakarta, Indonesia, Kalbe International handles trading and export of the Kalbe Farma group's full product portfolio across 27 countries — a direct Marketing Division in 12 markets (Singapore, Cambodia, Malaysia, Myanmar, Philippines, Vietnam, Sri Lanka, South Africa, Nigeria, Thailand, UAE) supplemented by trading partnerships in 15 additional countries. Its portfolio spans four categories: OTC (Woods, Procold, Mixagrip, Promag), Consumer health (Extrajoss, Hydrococo), Nutrition (Milna, Morinaga, Prenagen, Entrasol, Nulife, Fitbar, Diabetasol, Zee), and Prescription pharmaceuticals covering oncology (Paxus PM, Theracim/Cimaher, Rituxikal, Avamab, Oxaplat/Rexta, Doxekal/Brexel), neurology (Brainact/Citicol, Carq, Kalmeco, Citaz), nephrology (Hemapo, Nocid/Glomicid, Nevox-XR, Metrix, Hexilon, Nephrolit), and medical nutrition (Nephrisol, Nephrisol-D, Nutrican, Peptibren, Hepatosol, Peptisol).

The company's technology base relies on proprietary pharma platforms rather than digital/AI systems: Plant Cell Culture Technology for Paclitaxel formulation in oncology, Hydrophilic Gel Matrix for 24-hour extended-release metformin, dual-coated synbiotic probiotic formulations, and WHO PQ-certified manufacturing for institutional-grade antibiotics. Its go-to-market is hybrid B2B/B2C: enterprise sales to doctors, clinics, hospitals, and dialysis centers for prescription and medical nutrition products; pharmacy and wholesale distribution for OTC and ethical products; and direct-to-consumer e-commerce via Lazada and Shopee in Philippines and Vietnam, plus Shop Myanmar and the Southstar Drug pharmacy chain. The company also deploys consumer-facing digital tools — Allergy Check and a Nutrition Calculator — to drive engagement on kalbeinternational.com.

Revenue mechanics are not publicly disclosed at the Kalbe International subsidiary level; Kalbe Farma group reports consolidated results as a public company on the Indonesia Stock Exchange. Pricing is set by retailers and regional distributors rather than centrally, and the business model is asset-light international marketing rather than standalone R&D or manufacturing for export — the parent group retains production control across the value chain.

Name

Kalbe International

Legal name

Kalbe International

Website

https://kalbeinternational.com

Company type

Private

Operating status

Operating

Headcount range

251–500 employees

Short description

Kalbe International is the international marketing and export arm of PT Kalbe Farma Tbk, distributing OTC, consumer health, nutrition, and prescription pharmaceuticals across 27 countries through direct operations and trading partnerships.

Ownership category

akta.pro rank

Product category

Pharmaceutical Products

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Medical Nutrition & Meal Replacement (RTD, Bars, Powders) (CRADAGAN)

akta.pro secondary industries

Vitamins & Minerals (Single Nutrients) (CRADAGAB), Children’s Vitamins & Supplements (CRADAGAJ), Snack Bars (Granola, Protein, Cereal Bars) (CRADABAG)

Keywords

• Pharmaceutical products
• Nutritional supplements
• Over-the-counter medications
• Prescription pharmaceuticals
• Medical nutrition products

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain

Revenue model

1. Pharmaceutical Products: Trading/export of prescription pharmaceuticals manufactured under GMP by Kalbe Farma's group of companies.
2. OTC Products: Over-the-counter drugs sold through pharmacies and retail channels internationally.
3. Consumer Health Products: Consumer health and nutritional products including energy drinks, milk products, and health supplements sold through retail and e-commerce.
4. Nutritional Products: Wide range of nutritional products from specialized nutrition for women, infants, kids, to adult nutrition for healthy lifestyle sold globally.
5. Medical Nutrition Products: Specialized medical nutrition products for kidney disease, cancer, liver disease, and neurological conditions sold through pharmacies, hospitals, and clinics.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

Kalbe International is the international marketing arm of PT Kalbe Farma Tbk, handling trading and export of the parent group's pharmaceutical, OTC, consumer health, and nutritional products across 27 countries. The portfolio spans prescription pharmaceuticals (oncology, neurology, nephrology, antibiotics), OTC medications (cough, cold, digestive health), consumer health products (energy drinks, beverages), and specialized medical nutrition for chronic conditions (kidney disease, cancer, liver disease). Products are distributed through pharmacy and hospital networks, direct international marketing operations, and e-commerce marketplaces.

Product overview

Kalbe International is a pharmaceutical and healthcare company operating as the international marketing arm of Kalbe Farma's group, offering a diversified portfolio across four main product categories: OTC (over-the-counter) brands including Mixagrip, Procold, Woods, and Promag for consumer self-medication; Consumer brands like Extrajoss energy drink and Hydrococo beverages; Nutrition brands spanning infant formula (Milna, Morinaga), health bars (Fitbar), pregnancy nutrition (Prenagen), diabetes-specific nutrition (Diabetasol), and general adult nutrition (Entrasol, Nulife, Zee); and Prescription products including specialty therapeutic areas of Oncology (Paxus PM, Theracim/Cimaher, Rituxikal, Avamab, Oxaplat/Rexta, Doxekal/Brexel), Neurology (Brainact/Citicol, Carq, Kalmeco, Citaz), Nephrology (Hemapo, Nocid/Glomicid, Nevox-XR, Metrix, Hexilon, Nephrolit, Kalmeco), and General Ethical antibiotics and specialty medications. Additionally, Kalbe offers Medical Nutrition products for specialized patient needs including Nephrisol for pre-dialysis kidney patients, Nephrisol-D for dialysis patients, Nutrican for cancer/cachexia patients, Peptibren for neurological patients, Hepatosol for liver disease patients, and Peptisol for post-surgical recovery. The company also provides digital tools including an Allergy Check risk assessment tool and Nutrition Calculator for consumer engagement.

Differentiator

Problem solved

Functional benefit

Brands

• Promag: OTC brand for digestive health
• Woods
• Procold
• Mixagrip
• Fitbar
• Morinaga
• Extrajoss
• Entrasol
• Nulife
• Prenagen
• Milna
• Diabetasol
• Hydrococo
• Zee

Products and services

• Mixagrip

Quantifiable outcome

• Kalbe Farma is the largest publicly-listed pharmaceuticals company in Southeast Asia
• +1 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Tempo Scan Pacific: Indonesian pharmaceutical and consumer healthcare company with prescription, OTC, and consumer health brands. Closest direct domestic peer to Kalbe International, competing across the same product categories and Indonesian and regional pharmacy channels.
• Dexa Medica: Indonesia-based pharmaceutical group with prescription, OTC, and natural-product brands distributed across Southeast Asia. Direct peer to Kalbe International in oncology, antibiotics, and consumer health, targeting the same regional hospital and retail customers.

Broad incumbents

• Pfizer: Global pharmaceutical major with established prescription and oncology presence across Southeast Asia. Overlaps with Kalbe International in oncology (Paxus PM vs. originator paclitaxel), antibiotics (Levofloxacin WHO PQ), and hospital-channel distribution.
• Nestlé Health Science: Global medical nutrition and consumer health subsidiary of Nestlé, with leading brands across pediatric, adult, and disease-specific nutrition (Peptamen, Novasource). Directly comparable to Kalbe International's medical nutrition franchise (Nephrisol, Nutrican, Peptibren) and pediatric nutrition (Milna, Morinaga).
• Sanofi: Global pharmaceutical major with deep Southeast Asian operations across prescription, OTC (e.g., Magne-B6, Essentiale), and consumer health. Overlaps with Kalbe International in chronic-disease therapeutic categories and in OTC distribution into the same pharmacy and hospital channels across the 12 direct markets.
• GSK: Global pharmaceutical and consumer healthcare company with leading OTC brands (Panadol, Sensodyne, Strepsils) and a strong respiratory and vaccine portfolio. Competes head-to-head with Kalbe International's Mixagrip, Woods, and Procold brands across the same Southeast Asian pharmacy shelves.
• Bayer: Global pharma and consumer health group with strong OTC brands (Saridon, Aspirin, Claritin) and prescription presence in cardiovascular and oncology. Direct overlap with Kalbe International's OTC, neurology, and nephrology portfolios and similar multi-country distribution model in Southeast Asia.
• Abbott: Global healthcare company with a large nutritionals business (Ensure, Similac, PediaSure) and prescription pharma presence in Southeast Asia. Closely comparable to Kalbe International in adult and pediatric nutrition (Entrasol, Milna, Diabetasol, Prenagen) and chronic-disease medical nutrition.

Emerging players

• Yiling Pharmaceutical: Chinese pharmaceutical company expanding internationally, with strength in cardiovascular, oncology, and traditional-Chinese-medicine-derived products. Comparable to Kalbe International as a regional Asian player pursuing international diversification across similar therapeutic categories.

Others

• PT Kalbe Farma Tbk: Parent company of Kalbe International and the largest publicly-listed pharmaceutical company in Southeast Asia. Comparable as the originator of Kalbe International's full product portfolio across prescription, OTC, consumer health, and nutrition, and the source of its manufacturing, R&D, and capital backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/kalbe-pharma-indonesia-kalbe-international-division-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kalbe International